TICKERNERD
Menu
HIMSHIMSHealthcare · Drug Manufacturers - Specialty & Generic

HIMS Stock Forecast: Hims & Hers Health, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$34
+6.06% on the day

The 15 Wall Street analysts covering Hims & Hers Health, Inc. hold a median 12-month price target of $30 — -11.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$7.9B
Ticker Nerd rank
19 / 100
Median analyst target
$30
Analysts covering
15
Total return, dividends reinvested
1W
+20.0%
1M
+3.2%
YTD
+4.1%
1Y
−23.1%
From 52W high
−46.2%
From 52W low
+132.7%
$15
$63
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HIMS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Hims & Hers Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
67
Accruals
57
Revisions
42
Value
38
Growth
37
Momentum
32
Size
18
Issuance
17
Volatility
10

Quality (67): The business earns solid, repeatable profits on what it owns.

Volatility (10): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HIMS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HIMS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26HIMSHigh $42Median $30Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
3 Buy11 Hold1 Sell
Low $23Median $30High $42

The green dot is the last close — the median target sits −11.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
21 Aug 2026BarclaysMaintainsOverweight$39 → $35
11 Aug 2026B of A SecuritiesMaintainsNeutral$30 → $32
11 Aug 2026CitigroupMaintainsNeutral$35 → $33
11 Aug 2026Deutsche BankMaintainsHold$25 → $26
11 Aug 2026Morgan StanleyMaintainsEqual-Weight$21 → $28
11 Aug 2026NeedhamMaintainsBuy$35 → $42
11 Aug 2026TD CowenMaintainsHold$25 → $30
24 July 2026Truist SecuritiesMaintainsHold$23 → $27
24 July 2026Truist SecuritiesMaintainsHold—
23 July 2026CitigroupMaintainsNeutral—
23 July 2026CitigroupMaintainsNeutral$28 → $35
9 July 2026B of A SecuritiesMaintainsNeutral$36 → $37
9 July 2026B of A SecuritiesMaintainsNeutral—
1 July 2026B of A SecuritiesMaintainsNeutral—
1 July 2026Canaccord GenuityMaintainsBuy—
18 June 2026BarclaysMaintainsOverweight—
26 May 2026B of A SecuritiesMaintainsNeutral—
22 May 2026Truist SecuritiesMaintainsHold—
19 May 2026B of A SecuritiesMaintainsNeutral—
13 May 2026B of A SecuritiesMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HIMS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

HIMS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Hims & Hers Health, Inc. (HIMS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
57.1×

Cheaper than 13% of US stocks

Price / sales
3.1×

Cheaper than 43% of US stocks

Price / book
24.3×

Cheaper than 5% of US stocks

EV / EBITDA
−843.7×

Cheaper than 99% of US stocks

Growth & margins
Revenue growth (YoY)
38.2%

Higher than 82% of US stocks

Earnings growth (YoY)
3.8%

Higher than 40% of US stocks

Gross margin
65.2%

Higher than 79% of US stocks

Operating margin
−12.8%

Higher than 23% of US stocks

Net margin
−5.5%

Higher than 23% of US stocks

Returns & dividend
Return on equity
−32.0%

Higher than 26% of US stocks

Return on assets
−2.2%

Higher than 36% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

HIMS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
HIMSHims & Hers Health, Inc.$7.9B
19
ALKSAlkermes Plc$8.0B
62
LNTHLantheus Holdings, Inc.$6.5B
86
KNSAKiniksa Pharmaceuticals International Plc$6.1B
98
LQDALiquidia Corp.$5.9B
78
AMRXAmneal Pharmaceuticals, Inc.$5.6B
80
ELANElanco Animal Health, Inc.$12.0B
99

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Hims & Hers Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HIMS news & analysis

Kaplan Fox & Kilsheimer LLP Alerts Investors of Hims & Hers Health, Inc. (HIMS) to an Investigation of Potential Securities Law Violations

Newsfile Corp · 21 Aug 2026negative

Law firm Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities law violations against Hims & Hers Health, Inc. The firm is contacting investors who suffered losses or who have information that could assist in the investigation.

Why it matters — A securities-law investigation into Hims & Hers introduces potential regulatory and legal risk that HIMS watchers would want to monitor.

HIMS INVESTIGATION: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm

GlobeNewsWire · 21 Aug 2026negative

Kessler Topaz Meltzer & Check, LLP, a securities litigation law firm, announced it is investigating potential violations of federal securities laws by Hims & Hers Health, Inc. The firm is reaching out to investors who purchased HIMS securities and experienced significant financial losses.

Why it matters — A securities fraud investigation signals potential legal and regulatory exposure for HIMS that investors should monitor.

HIMS Stock More Than Doubled in 6 Months: What's Driving the Rally?

Zacks Investment Research · 21 Aug 2026positive

Hims & Hers Health's stock more than doubled over six months, with the rally driven by branded weight-loss growth, international expansion, AI efficiencies, and a broader specialty portfolio.

Why it matters — The article highlights the key growth drivers behind HIMS's recent stock performance, giving watchers insight into the company's current momentum.

Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access

Benzinga · 19 Aug 2026neutral

Hims & Hers Health CEO Andrew Dudum defended the telehealth company amid a U.S. Federal Trade Commission lawsuit concerning data privacy and advertising practices, while also pledging expanded patient access. The company rejected the privacy allegations leveled against it.

Why it matters — A HIMS watcher would care because the FTC lawsuit touches on data privacy and advertising practices central to the company's telehealth operations, while the CEO's response signals how leadership is addressing regulatory scrutiny.

Hims & Hers: Buying The Margin Dip

Seeking Alpha · 19 Aug 2026positive

Hims & Hers Health is rated a buy at current levels, supported by robust international expansion and product innovation. International revenue grew over 17-fold year-over-year to $131M, driven by the Eucalyptus acquisition and new markets, with a $600M+ 2026 target, while AI investment aims to reduce customer-support costs and improve retention with payback expected in 12–18 months.

Why it matters — A HIMS watcher would care because the item highlights accelerating international revenue growth and AI-driven cost-efficiency efforts that could shape the company's near-term financial trajectory.

FAQ

Frequently asked questions about HIMS stock

What is the HIMS stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Hims & Hers Health, Inc. have a median 12-month price target of $30, with estimates ranging from $23 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HIMS stock a buy right now?

Of the 15 analysts covering Hims & Hers Health, Inc., 3 rate it a Buy, 11 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Hims & Hers Health, Inc. 19 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HIMS?

As at 22 Aug 2026, Hims & Hers Health, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (67 of 100).

Will HIMS stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies -11.2% from the last close, and Ticker Nerd's factor model ranks Hims & Hers Health, Inc. 19 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HIMS stock forecast for 2030?

No analyst covering Hims & Hers Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HIMS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $42 over the next 12 months.

How has HIMS stock performed over the past year?

Hims & Hers Health, Inc. returned -23.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Hims & Hers Health, Inc. do?

Hims & Hers Health, Inc. is a consumer-focused digital health and wellness company that operates a multi-specialty telehealth platform.

What is the latest news on HIMS?

The most recent item we track (Newsfile Corp, 21 Aug 2026): "Kaplan Fox & Kilsheimer LLP Alerts Investors of Hims & Hers Health, Inc. (HIMS) to an Investigation of Potential Securities Law Violations". Law firm Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities law violations against Hims & Hers Health, Inc. The firm is contacting investors who suffered losses or who have information that could assist in the investigation.

Company

About Hims & Hers Health, Inc.

Hims & Hers Health, Inc. is a consumer-focused digital health and wellness company that operates a multi-specialty telehealth platform. The firm connects individuals with licensed healthcare professionals through its websites and mobile applications, enabling convenient access to medical consultations and, when appropriate, prescription therapies and personalized treatment plans. Its platform spans key areas such as sexual health, hair care, dermatology, mental health, hormone and primary care, and weight loss, complemented by comprehensive laboratory testing and curated non-prescription wellness products, supplements, and personal care items. Hims & Hers Health, Inc. uses a direct-to-consumer, largely subscription-based model, with medications fulfilled via licensed pharmacies and over-the-counter products sold through its digital storefronts. The company serves customers primarily in the United States, with additional reach in markets such as the United Kingdom and Canada, positioning itself as an accessible, digital-first alternative to traditional healthcare for adults seeking discreet and convenient care. Founded in 2017 and headquartered in San Francisco, California, Hims & Hers Health, Inc. today plays a notable role in the telehealth and online pharmacy segments of the healthcare market.

CEO Mr. Andrew Dudum · 2,442 employees · United States · https://www.hims.com